Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sana Biotechnology, Inc.NASDAQ: SANA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $5.66M fell 19.4% year over year, ahead of the -32.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -19.4% holds above the trailing-twelve-month pace of -32.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 25.46M USD
- Year-over-year change
- -32.4%
- 4-year CAGR
- +3.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.46M | -32.4% |
| FY2024 | 2024-12-31 | 37.68M | +6.0% |
| FY2023 | 2023-12-31 | 35.53M | -7.3% |
| FY2022 | 2022-12-31 | 38.34M | +71.4% |
| FY2021 | 2021-12-31 | 22.36M | — |
Stock-Based Compensation vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 stock-based compensation of $24.1M is the 5th largest of the 11 companies compared; the peer median is $15.19M.
- Its year-over-year change of -32.3% is the 5th highest of 11, against a peer median of -39.2%.
- Over three fiscal years its annual growth of -12.7% compares with a peer median of -13.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.91M | +2.8% | +19.1% | 220.8% | |
| LTM Sep 2026 | $69.68M | -8.8% | -9.5% | 276.8% | |
| LTM Mar 2026 | $34.28M | -12.0% | +8.8% | — | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $24.1M | -32.3% | -12.7% | — | |
| LTM Mar 2026 | $21.47M | -43.3% | -31.8% | 340.0% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| LTM Mar 2026 | $8.91M | -28.8% | -19.0% | 19.8% | |
| LTM Sep 2026 | $7.7M | -87.8% | — | 0.6% | |
| LTM Mar 2026 | $6.29M | -72.4% | -43.4% | 27.2% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| Peer median (excluding SANA) | $15.19M | -39.2% | -13.8% | 27.2% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.36M | 38.34M | 35.53M | 37.68M | 25.46M |
| Change in Working Capital | 9.8M | 7.54M | 18.61M | (1.19M) | (10.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (266K) | 1.06M | 1.03M | 1.38M | (3.55M) |
| Other Working Capital | 10.07M | 6.48M | 17.58M | (2.56M) | (6.57M) |
| Other Non-Cash Items | 61.64M | (82.08M) | (49.03M) | (10.28M) | 72.24M |
| Operating Cash Flow | (251.05M) | (290.05M) | (253.58M) | (223.15M) | (143.83M) |
| Capital Expenditures | (29.86M) | (20.88M) | (20.03M) | (33.43M) | (938K) |
| Acquisitions (Net) | 0 | (231.44K) | (192.04K) | 0 | 1.43M |
| Purchases of Investments | (491.39M) | (78.69M) | (157.74M) | (226.06M) | (87.29M) |
| Sales of Investments | 280.03M | 310.13M | 349.79M | 276.95M | 46.56M |
| Other Investing Activities | (4.57M) | 231.44K | 192.04K | 17.45M | 0 |
| Investing Cash Flow | (245.8M) | 210.56M | 172.01M | 17.45M | (40.24M) |
| Debt Repayment | 0 | 0 | 0 | 7.74M | (347K) |
| Common Stock Issued | 631.75M | 4.91M | 31.65M | 181M | 129.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 11.01M | 0 |
| Financing Cash Flow | 631.75M | 4.91M | 31.65M | 199.75M | 128.73M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 134.9M | (74.58M) | (49.92M) | (5.95M) | (55.33M) |
| Free Cash Flow | (280.92M) | (310.93M) | (273.61M) | (256.58M) | (144.77M) |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.